Combining viral vector transduction and brain clearing using the CLARITY method allows the investigation of a large number of neurons and astrocytes simultaneously.
Combining viral vector transduction and tissue clearing using the CLARITY method makes it possible to simultaneously investigate several types of brain cells and their interactions. Viral vector transduction enables the marking of diverse cell types in different fluorescence colors within the same tissue. Cells can be identified genetically by activity or projection. Using a modified CLARITY protocol, the potential sample size of astrocytes and neurons has grown by 2-3 orders of magnitude. The use of CLARITY allows the imaging of complete astrocytes, which are too large to fit in their entirety in slices, and the examination of the somata with all their processes. In addition, it provides the opportunity to investigate the spatial interaction between astrocytes and different neuronal cell types, namely, the number of pyramidal neurons in each astrocytic domain or the proximity between astrocytes and specific inhibitory neuron populations. This paper describes, in detail, how these methods are to be applied.
In recent years, the knowledge of astrocyte function and how they interact with neuronal circuits has increased dramatically. Astrocytes can influence plasticity1,2, assist in neuronal postinjury recovery3,4, and even induce de novo neuronal potentiation, with recent studies exhibiting the importance of astrocytes in memory acquisition and reward, previously regarded as purely neuronal functions5,6,7. A feature of particular interest in astrocyte research is the spatial arrangement of the cells, which maintain unique spatial organizations in the hippocampus and other brain structures8,9,10. Unlike the neuronal dendrites that intertwine between cell somata, hippocampal astrocytes inhabit visually distinguishable territories with slight overlap between their processes, creating distinct domains8,11,12,13. The evidence supporting the participation of astrocytes in neuronal circuits does not support the lack of detailed anatomical description of such populations and the neurons in their domains14.
Viral vector transduction procedures, along with transgenic animals (TG), have been popularized as a toolset to investigate brain structures, functions, and cell interactions15,16. The utilization of different promoters allows the targeting of specific cells according to their genetic properties, activation levels17,18, or projection targets. Different viruses can express different colored fluorophores in different populations. A virus can be combined with the endogenous expression of fluorophores in TG, or TG animals can be used without the need for viruses. These techniques are widely used for neuronal marking, and some labs have started using them with modifications specialized for targeting other cell types, such as astrocytes5,9,19.
The CLARITY technique, first described in 201320,21, enables the study of thick brain slices by making the entire brain transparent while leaving the microscopic structures intact. By combining the two methods-viral vector transduction and tissue clearing-the option of examining the spatial interactions between different cell type populations is now available. Most astrocyte-neuron interaction studies were performed on thin brain slices, resulting in images of incomplete astrocytes due to their large domains, thus radically restricting the number of analyzed cells. The use of the CLARITY technique allows single-cell resolution characterization of cell populations in large-scale volumes simultaneously. Imaging fluorescently tagged cell populations in clear brains does not deliver synaptic resolution but permits thorough characterization of the spatial interactions between astrocytes and a variety of neuronal cell types.
For that reason, we harnessed these state-of-the-art techniques to investigate the properties of astrocytes throughout the dorsal CA1, imaging all lamina (Stratum Radiatum, pyramidal layer, and Stratum Oriens). We measured tens of thousands of astrocytes (with viral penetrance of >96%5), thereby analyzing the information of the entire astrocytic population around CA1. With efficient penetrance of the neuronal markers, we could record the interactions between the entire population of CA1 astrocytes and the four types of neuronal cells-parvalbumin (PV), somatostatin (SST), VIP inhibitory neurons, and excitatory pyramidal cells9.
Several experiments were performed using a combination of fluorescence from TG animals and differently colored viral vectors (all inhibitory cells), while others (excitatory) utilized two viral vectors expressing different fluorophores under different promoters9. This paper presents a detailed protocol, including the tagging of the desired cells in the brain, making the brain transparent using a modified CLARITY procedure, as well as imaging and analyzing complete brain structures, using various procedures and software.
Experimental protocols were approved by the Hebrew University Animal Care and Use Committee and met the guidelines of the National Institute of Health Guide for the Care and Use of Laboratory Animals.
1. Viral vector transduction
NOTE: Viral vector transduction is used to express fluorophores in the brain.
2. CLARITY
NOTE: This method renders the brain transparent within 2-6 weeks.
3. Chamber preparation
NOTE: Each sample requires a slide with an imaging chamber in which the sample will be placed.
4. Imaging (confocal or two-photon)
Successful clearing of thick brain tissue slices results in a new range of questions that can be asked regarding the properties of large cell populations as opposed to the properties of single cells or neighboring groups of cells. To achieve successful results, one should strictly adhere to the CLARITY protocol, as there is a wide range of parameters that need to be considered to reduce the variance between samples (e.g., percentage of clarity, fluorescence information, swollenness parameters).
Figure 1 describes the entire clearing process from fluorescent protein expression validation through all the stages of the clearing method. Figure 2 describes how to prepare a chamber for the clarified tissue, optimal for imaging under a two-photon or confocal microscope. The materials required in this protocol are extremely inexpensive relative to other protocols of chamber preparation.
Figure 3 presents the cube described in Video 1, where over 300 astrocytes are shown in a cleared section of the CA1 part of a mouse hippocampus. Figure 4 presents the cube described in Video 2, where both astrocytes and excitatory neuronal somata are shown in thick transparent tissue. Figure 5 presents an entire hemisphere, as described in Video 3. Brain-wide neuronal projections are displayed from the dorsal CA1 (green, GFP) and the ventral CA1 (red, TdTomato).
Video 1 presents a thick image of hippocampal astrocytes (>300) acquired with a two-photon microscope after a CLARITY procedure. Fluorescence was provided by viral vector transduction specific to astrocytes. Video 2 presents the spatial proximity between astrocytes and the nuclei of hippocampal pyramidal cells. Video 3 traces axonal bundles across an entire hemisphere; axons project from the primary motor cortex and are traced back from the spinal cord. Another bundle is traced from the dorsal hippocampus toward the Supra Mammillary bodies. Lastly, it traces a red bundle of axons from the Mammillary bodies toward their origin at the ventral hippocampus. All marked cells are exclusively excitatory.
Figure 1: Detailed description of the clearing process. (A) Validation of fluorophore expression. In this example, all astrocytes in the CA1 part of a mouse hippocampus express a red protein (TdTomato, imaged in magenta), and all excitatory neurons express a green protein in their nuclei (H2B-GFP). This image was acquired using a 2-photon microscope. The image was taken using a water immersion 16x objective (0.8 NA) with magnification of 2.4 to obtain a 652 x 483 µm field of view, at 15.5 frames/s and a z-stack with 0.937 µm intervals between the planes. The specificity and penetrance were verified by immunohistochemistry9. (B) Transferring the N2 gas from the tank into the tube holding the brain requires a pipe with a needle at its end. (C) Air inside the tube is replaced with N2 by creating two holes, one (upper arrow) for the inflow of N2via the needle connected to the piping from the gas tank and another (bottom arrow) for outflow. (D) Covering the holes with modeling clay immediately after degassing prevents the N2 from exiting the tube. (E) Heating the degassed solution for 3.5 h in a warm bath. (F) Successful polymerization results in a brain embedded in gelled HS. Gas bubbles might be trapped in the polymer. (G) Immediately after extraction from the gel is the best point for the brain to be cut into the desired thickness. (H) Perforated tubes allow the flow of the solution on the stirrer to reach the sample. (I) Brains inside perforated tubes are held vertically by a self-made holder of a size made to fit a 2 L beaker, standing on a hotplate stirrer. (J) Example of a brain that is not clear enough. The sample should be stirred in the CS2 for approximately one more week. (K) Example of a sufficiently clear brain. (L) When inserting the clear brain into PBST, the tissue becomes whiter than before. This change of color is due to the Triton and will disappear when moved from this solution to the next. (M) After >24 h in the RIMS, the brain will become fully transparent again. Abbreviations: GFP = green fluorescent protein; NA = numerical aperture; HS = hydrogel solution; CS2 = Clearing Solution 2; PBST = Phosphate-buffered saline containing 0.5% Triton X-100; RIMS = Refractive Index Matching Solution. Please click here to view a larger version of this figure.
Figure 2: Chamber preparation. (A) The first layer of hot glue walls covers the edges of a slide and leaves a space wide enough to contain the brain without touching the walls. One hole is left in the upper-left corner of the slide. (B) Adding layer after layer to reach the height of the tissue. (C) Straight coverslip (white arrow) seals the chamber. (D) Chamber filled with RIMS through the hole in the chamber walls. (E) The chamber is filled with RIMS leaving no air bubbles. (F) Sealing the hole in the chamber with hot glue to prevent any leakage. Side view. (G) At this stage, any hot glue remnant extending over the edges of the slide should be cut off the chamber. (H) Fully prepared chamber, ready for imaging under the microscope. Abbreviation: RIMS = Refractive Index Matching Solution. Please click here to view a larger version of this figure.
Figure 3: All imaged astrocytes (AAV1-GFAP::TdTomato, red) in a cleared hippocampus. A single frame from Video 1 capturing all imaged astrocytes (AAV1-GFAP::TdTomato, red) in a cleared hippocampus. All details of the image properties are described under Video 1. Please click here to view a larger version of this figure.
Figure 4: Astrocytes (AAV1-GFAP::TdTomato, red) and hippocampal pyramidal cells nuclei (AAV5-CaMKII::H2B-eGFP, green) in thick transparent tissue. A single frame from Video 2 showing both astrocytes (AAV1-GFAP::TdTomato, red) and hippocampal pyramidal cells nuclei (AAV5-CaMKII::H2B-eGFP, green) in thick transparent tissue. Please click here to view a larger version of this figure.
Figure 5: Green axons (AAV5-CaMKII::eGFP, green) and red axons (AAV5-CaMKII::TdTomato). A single frame from Video 3 showing both types of axons derived from several locations in a mouse brain that can be traced throughout an entire hemisphere. Please click here to view a larger version of this figure.
Video 1: Footage of >1 mm thick slice of hippocampal dorsal CA1 astrocytes (AAV1-GFAP::TdTomato, red). The video was acquired with a two-photon microscope using a 16x objective (0.8 NA) with magnification of 2.4 following a CLARITY procedure. Similar to Figure 1A, the z-stack interval was set to 0.937 µm. Fluorescence was provided by viral vector transduction specific to astrocytes. The number of astrocytes in this cube is >300, and most processes are available for analysis in most cells. Abbreviations: NA = numerical aperture; AAV = adeno-associated virus; GFAP = glial fibrillary acidic protein. Please click here to download this Video.
Video 2: Astrocytes and excitatory neurons nuclei in a 3D cube. The cube contains all lamina of the dCA1 under the optical conditions mentioned for Figure 1A and Video 1. This cube exhibits the spatial proximity between astrocytes (AAV1-GFAP::TdTomato, red) and the nuclei of hippocampal pyramidal cells (AAV5-CaMKII::H2B-eGFP, green). Abbreviations: AAV = adeno-associated virus; GFAP = glial fibrillary acidic protein; CAMKII = calcium/calmodulin-dependent protein kinase II; eGFP = enhanced green fluorescent protein; H2B = histone 2B. Please click here to download this Video.
Video 3: Tracing axonal bundles across an entire hemisphere. Green axons (AAV5-CaMKII::eGFP, green) ending at the spinal cord are easily traced back to the primary motor cortex (more than 7 mm apart). From the hippocampus (dorsal side), another bundle is traced toward the Supra Mammillary bodies (most ventral side of the brain), a trace of almost 3 mm long. The second half of the video traces a red bundle of axons (AAV5-CaMKII::tdTomato) originating at the ventral hippocampus back from their target location at the Mammillary bodies. The image was taken under an Olympus scanning laser confocal microscope FV1000 using a 4x objective (0.16 NA), and multiple ROIs were combined using MATL FluoView-feature to present the entire hemisphere. Abbreviations: AAV = adeno-associated virus; CAMKII = calcium/calmodulin-dependent protein kinase II; eGFP = enhanced green fluorescent protein; NA = numerical aperture; MATL = multiple area time-lapse. Please click here to download this Video.
Hydrogel Solution (1 L) | |
Material | Amount |
VA-044 Initiator | 2.5 g |
PFA 4% | 900 mL |
Acrylamide (40%) | 50 mL |
Bisacrylamide (2%) | 50 mL |
Table 1: Preparation of hydrogel solution (1 L). Hydrogel solution must be prepared on an ice-cold surface. The order in which the ingredients are mixed is not important. Note that the total percentage of acrylamide is 2% unlike similar protocols that use either 1%17 or 4%22.
Clearing Solutions (1 L) | ||
Material | Amount | |
CS1 | CS2 | |
Boric acid (M.W. = 61.83 g/mol) | 12.366 g | 3.4 g |
SDS | 80 g | 80 g |
Tris base (M.W. = 121.14 g/mol) | 0 | 12.1 g |
Distilled Water (DW) | Fill to 1 L | Fill to 1 L |
NaOH | pH 8.5 | |
1 L of Phosphate-buffered Saline with 0.5% Triton X-100 | ||
Material | Amount | |
PBS | 995 mL | |
Triton X-100 | 5 mL |
Table 2: Preparation of clearing solutions 1 and 2 (1 L) and 1 L of Phosphate-buffered Saline with 0.5% Triton X-100. The clearing solutions can be prepared in advance and kept at room temperature for a long period. Any solution containing boric acid and SDS should be handled under a fume hood to avoid inhalation or skin contact with either SDS or boric acid. The NaOH in CS1 should be added last to set the pH at 8.5. Each brain sample should be placed in at least 5-25 mL of CS1 and kept overnight for sufficient diffusion. Abbreviations: CS1 = clearing solution 1; SDS = sodium dodecyl sulfate; M.W. = molecular weight.
Product Name | Primary advantage | Primary disadvantage |
RapiClear | Sample stays transparent | Tissue swelling |
RapiClear CS | Sample shrinks back to normal size | Sample may lose transparency |
Table 3: RIMS options with advantages and disadvantages. Rapiclear (RC, RI = 1.47) or CLARITY-specific Rapiclear (CSRC, RI = 1.45). The primary difference between these two solutions is that while the CSRC shrinks the clear brain back to its original size, the RC solution does not, leaving the cleared sample slightly swollen. Abbreviation: RI = refractive index.
Tissue clearing methods present a revolutionary tool in brain research, inviting questions that could not previously have been asked. From targeting the properties of a small group of cells, a single cell, or even a single synapse, CLARITY now enables the targeting of total cell populations or long-range connectivity features by using relevant fluorophores.
The outcome of the fluorophore expression and CLARITY procedure combination is not binary; many factors may interfere with the procedure leading to suboptimal results. First, the fluorophore expression must be verified in advance. As the CLARITY procedure causes some information loss, sufficient fluorophore protein expression is crucial to the validity of the image at the end of the CLARITY process. Second, the transcranial perfusion must be handled carefully, ensuring that all blood exits the brain, because the autofluorescence of blood will lead to unreliable data in thick slices. Third, all parameters discussed in the protocol must be handled in each step of the clearing process with precision, e.g., O2 residue in the HS before polymerization or temperature imprecision at each stage will prevent the chemical reaction between the active materials from occurring.
Previous protocols17,22 recommend different concentrations of acrylamide in the HS. The primary purpose of acrylamide is to better fixate the molecules with amine residues (proteins and nucleic acids). Slight alterations to the concentration greatly impact the entire clearing process: if the fixation is too compact, the lipid molecules will not disconnect from the tissue, and the clearing process will be unnecessarily protracted or result in opaque brains. Lower concentrations of acrylamide, however, will not adequately maintain the brain structure once devoid of lipids. In this protocol, the acrylamide percentage is set to provide the delicate balance of fixated yet clear tissue.
Most of the clearing process takes place in CS2, and the tissue clarity level should be tested daily. PBST cleanup is an essential step between the Clearing solutions and the refractive index matching solutions because it cleans the residual SDS molecules, which may interact with the RIMS. It is also possible to keep the clear tissue in PBST (0.5%) indefinitely if chamber preparation is not yet needed.
When placing the brain in the RIMS, one should become familiar with the benefits and limitations of the solutions. For example, RapiClear will cause complete transparency even in almost-cleared tissues, but will also cause some swelling, which should not be neglected when analyzing the data. Previous measurements9 suggest equal expansion along all axes (i.e., dorsoventral, anterior-posterior, and lateral-medial axes), making it possible to calculate the index of swelling by comparison to thin slices from the same brain region. Using CLARITY-Specific RapiClear eliminates the swelling; however, if any SDS leftovers remain in the tissue, they will aggregate into non-transparent masses.
Another benefit of this modified protocol is its cost. Previous protocols suggest different glue types to create a chamber that can hold the brain in RIMS. In this protocol, we simply use hot glue. It does not react with the solutions, is available to purchase everywhere, is easy to use, and is significantly cheaper than the glues suggested before.
Data acquired from the imaging of thick brain samples can describe entire cell populations, connectivity across brain structures, or the tracking of a single axon across large distances (Video 3). Although questions regarding these characteristics have been asked before, the validity of the data now achievable using thick brain slices greatly improves upon prior, mistake-prone methods of thin-slice image overlay.
The CLARITY process grants successful and uniform clearing of thick slices-from several millimeters to full brain imaging. The passive clearing (i.e., not using ETC) diminishes the risk of harm to the tissue, and the time for which samples are immersed in clearing solutions so that it does not affect the high efficiency of protein conservation.
The authors have nothing to disclose.
This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 803589), the Israel Science Foundation (ISF grant No. 1815/18), and the Canada-Israel grants (CIHR-ISF, grant No. 2591/18). We thank Nechama Novick for commenting on the whole manuscript.
AAV1-GFAP::TdTomato | ELSC Vector Core Facility (EVCF) | viral vector used to detect astrocytes | |
AAV5-CaMKII::eGFP | ELSC Vector Core Facility (EVCF) | viral vector used to detect neurons | |
AAV5-CaMKII::H2B-eGFP | ELSC Vector Core Facility (EVCF) | viral vector used to detect neuronal nuclei | |
AAV5-CaMKII::TdTomato | ELSC Vector Core Facility (EVCF) | viral vector used to detect neurons | |
Acrylamide (40%) | Bio-rad | #161-0140 | |
Bisacrylamide (2%) | Bio-rad | #161-0142 | |
Boric acid | Sigma | #B7901 | Molecular weight – 61.83 g/mol |
Confocal microscope, scanning, FV1000 | Olympus | 4x objective (UPlanSApo, 0.16 NA) | |
Imaris software | Bitplane, UK | A software that allows 3D analysis of images | |
NaOH | Sigma | #S5881 | |
PBS | |||
PFA 4% | EMS | #15710 | |
RapiClear | SunJin lab | #RC147002 | |
RapiClear CS | SunJin lab | #RCCS002 | |
SDS | Sigma | #L3771 | |
SyGlass software | A software that allows 3D analysis of images using virtual reality | ||
Tris base 1 M | Bio-rad | #002009239100 | Molecular weight – 121.14 g/mol |
Triton X-100 | ChemCruz | #sc-29112A | |
Two photon microscope | Neurolabware | Ti:sapphire laser (Chameleon Discovery TPC, Coherent), GaAsP photo-multiplier tubes (Hamamatsu, H10770-40) , bandpass filter (Semrock), water immersion 16x objective (Nikon, 0.8 NA) | |
VA-044 Initiator | Wako | #011-19365 |